SAN
DIEGO, Nov. 22, 2023 /PRNewswire/ -- Regulus
Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company
focused on the discovery and development of innovative medicines
targeting microRNAs (the "Company" or "Regulus"), today announced
that CEO Jay Hagan will be
participating in a fireside chat at the 6th Annual Evercore ISI
HealthCONx Conference on Wednesday November
29, at 10:25 a.m. ET.
A replay of the live presentation will be available under
"Events and Presentations" through the investor relations section
of the Company's website
at https://ir.regulusrx.com/events and archived for 90
days following the presentation date.
About Regulus
Regulus Therapeutics Inc. (Nasdaq: RGLS) is a biopharmaceutical
company focused on the discovery and development of innovative
medicines targeting microRNAs. Regulus has leveraged its
oligonucleotide drug discovery and development expertise to develop
a pipeline complemented by a rich intellectual property estate in
the microRNA field. Regulus maintains its corporate headquarters in
San Diego, CA.
Forward-Looking Statements
Statements contained in this presentation regarding matters that
are not historical facts are "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995, including statements associated with the Company's RGLS8429
program, the expected timing for initiating clinical studies,
potentially achieving therapeutic efficacy and clinical translation
for ADPKD patients, the expected timing for reporting topline data,
the timing and future occurrence of other preclinical and clinical
activities and the expected length of our cash runway. Because such
statements are subject to risks and uncertainties, actual results
may differ materially from those expressed or implied by such
forward-looking statements. Words such as "believes,"
"anticipates," "plans," "expects," "intends," "will," "goal,"
"potential" and similar expressions are intended to identify
forward-looking statements. These forward-looking statements are
based upon Regulus' current expectations and involve assumptions
that may never materialize or may prove to be incorrect. Actual
results and the timing of events could differ materially from those
anticipated in such forward-looking statements as a result of
various risks and uncertainties, which include, without limitation,
the approach we are taking to discover and develop drugs is novel
and may never lead to marketable products, preliminary or initial
results may not be indicative of future results, preclinical and
clinical studies may not be successful, risks related to regulatory
review and approval, risks related to our reliance on third-party
collaborators and other third parties, risks related to
intellectual property, risks associated with the process of
discovering, developing and commercializing drugs that are safe and
effective for use as human therapeutics and in the endeavor of
building a business around such drugs, and the risk additional
toxicology data may be negative and our need for additional
capital. These and other risks are described in additional detail
in Regulus' filings with the Securities and Exchange Commission,
including under the "Risk Factors" heading of Regulus' most
recently filed quarterly report on Form 10-Q. All forward-looking
statements contained in this press release speak only as of the
date on which they were made. Regulus undertakes no obligation to
update such statements to reflect events that occur or
circumstances that exist after the date on which they were
made.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/regulus-therapeutics-to-present-at-the-6th-annual-evercore-isi-healthconx-conference-301994900.html
SOURCE Regulus Therapeutics Inc.